Volume 90, Issue 9 , Pages 1462-1468, September 2009
Effect of Baseline Spastic Hemiparesis on Recovery of Upper-Limb Function Following Botulinum Toxin Type A Injections and Postinjection Therapy
Abstract
Chang C-L, Munin MC, Skidmore ER, Niyonkuru C, Huber LM, Weber DJ. Effect of baseline spastic hemiparesis on recovery of upper-limb function following botulinum toxin type A injections and postinjection therapy.
Objective
To determine whether baseline hand spastic hemiparesis assessed by the Chedoke-McMaster Assessment influences functional improvement after botulinum toxin type A (BTX-A) injections and postinjection therapy.
Design
Prospective cohort study.
Setting
Outpatient spasticity clinic.
Participants
Participants (N=14) with spastic hemiparesis divided into 2 groups: Chedoke-McMaster Assessment Hand-Higher Function (stage≥4, n=5) and Chedoke-McMaster Assessment Hand-Lower Function (stage=2 or 3, n=9).
Interventions
Upper-limb BTX-A injections followed by 6 weeks of postinjection therapy.
Main Outcome Measures
Primary outcomes were Motor Activity Log-28 and Motor Activity Log items. Secondary outcomes were Action Research Arm Test (ARAT), Motor Activity Log-Self-Report, and Modified Ashworth Scale (MAS). Measures were assessed at baseline (preinjection), 6 weeks, 9 weeks, and 12 weeks postinjection.
Results
Primary and secondary outcomes improved significantly over time in both groups. Although no significant differences in ARAT or MAS change scores were noted between groups, Chedoke-McMaster Assessment Hand-Higher Function group demonstrated greater change on Motor Activity Log-28 (P=.013) from baseline to 6 weeks and Motor Activity Log items (P=.006) from baseline to 12 weeks compared to Chedoke-McMaster Assessment Hand-Lower Function group.
Conclusions
BTX-A injections and postinjection therapy improved hand function and reduced spasticity for both Chedoke-McMaster Assessment Hand-Higher Function and Chedoke-McMaster Assessment Hand-Lower Function groups. Clinicians should expect to see larger gains for persons with less baseline impairment.
Key Words: Botulinum toxin type A, Electric stimulation therapy, Muscle spasticity, Recovery of function, Rehabilitation, Stroke, Upper extremity
List of Abbreviations: ARAT, Action Research Arm Test, BTX-A, botulinum toxin type A, CMA, Chedoke-McMaster Assessment, FES, functional electrical stimulation, MAS, Modified Ashworth Scale
Supported by Allergan Inc; National Institutes of Health Post-Doctoral Training (grant no. T32 HD049307), and National Institutes of Health (grant no. K12 HD055931).
No commercial party having a direct financial interest in the results of the research supporting this article has or will confer a benefit on the authors or on any organization with which the authors are associated.
PII: S0003-9993(09)00341-4
doi:10.1016/j.apmr.2009.03.008
© 2009 American Congress of Rehabilitation Medicine. Published by Elsevier Inc. All rights reserved.
Volume 90, Issue 9 , Pages 1462-1468, September 2009
